Project Grant R01NS137222

Award Date 7/1/24
Completion Date 5/31/29
Dollars Obligated $459K
Funding Federal Agency
Office of the Director
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the cellular and synaptic mechanisms underlying cognitive disabilities in Down syndrome. The award to the University of Colorado-Denver will utilize a novel combination of two-photon microscopy, electrophysiology, chemogenetics, and pharmacological...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $429,000 to the Regents of the University of Michigan to conduct research on the molecular regulators of the GABAergic system in human neurons derived from control and trisomy 21 (Down syndrome) human embryonic stem cells. The primary goal is to discover the underlying mechanisms that cause...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
The National Institutes of Health Trans-NIH Research Support program awarded a $4,010,262 Project Grant to the University of Illinois to study the role of amyloid precursor protein in neurogenesis and Alzheimer's disease pathology in Down syndrome. The three-year grant will support research examining how overexpression of amyloid precursor protein, which is located on chromosome 21 and thus triplicated in Down syndrome, impacts neural stem cell proliferation, neuronal differentiation, and...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $3,317,325.00 to the University of California, Irvine to investigate the role of immune deregulation and nerve growth factor (NGF) dysfunction in the development of Alzheimer's disease (AD) in individuals with Down syndrome (DS). The key products and services to be delivered under this 5-year grant include: Utilizing a multi-pronged...
The University of California, San Diego (UCSD) was awarded a $1,698,323 Project Grant from the National Institute on Aging (CFDA 93.866 Aging Research) to develop and validate a mouse model for Alzheimer's disease in Down syndrome (DS-AD). The goal is to create a genetically modified mouse that replicates key pathological features of DS-AD, including amyloid plaques, congophilic angiopathy, and neurofibrillary tangles. In the initial R61 phase, the researchers will demonstrate feasibility,...
The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
The Trustees of the University of Pennsylvania received a $3.7 million Project Grant award from the Department of Health and Human Services National Institutes of Health Office of the Director to address co-occurring conditions in individuals with Down syndrome. Funded under the Trans-NIH Research Support program (CFDA 93.310), the three-year project will test whether reducing proteostatic stress with the FDA-approved small molecule 4-phenylbutyrate can ameliorate sleep deficits, metabolic...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will fund research to investigate gastrointestinal dysfunction in Down syndrome. The $232,875 award to Virginia Commonwealth University will support a 2-year study to test the hypothesis that trisomy 21 in Down syndrome leads to altered voltage-gated calcium currents in smooth muscle of the distal colon,...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $322,000.00 to Case Western Reserve University to perform the following: Analyze electroencephalographic (EEG) and plasma Alzheimer's disease (AD) biomarker data collected during a previous clinical trial studying the effects of the drug memantine on adolescents and young adults with Down syndrome. The analysis will examine the...

MOLECULAR REGULATORS OF GABAERGIC SYSTEMS THAT UNDERLIE COMORBIDITIES IN DOWN SYNDROME - PROJECT SUMMARY DOWN SYNDROME (DS), WHICH IS CAUSED BY FULL OR PARTIAL TRISOMY OF HUMAN CHROMOSOME 21 (HSA21), PRESENTS VARIOUS NEUROLOGICAL FEATURES, INCLUDING INTELLECTUAL DISABILITY, EPILEPSY, AND ALZHEIMER'S DISEASE (AD). ALTHOUGH SOME HSA21 GENES HAVE BEEN IDENTIFIED AS KEY CONTRIBUTORS TO SOME OF THESE DISEASES, THE PATHOGENETIC MECHANISMS THAT LINK THE TRIPLICATION OF HSA21 GENES TO MOST DS-RELATED DISEASES REMAIN UNKNOWN. PARTICULARLY, VERY LITTLE IS KNOWN ABOUT WHETHER ANY OF THESE DISEASES SHARE COMMON MECHANISMS. FOR EXAMPLE, WE DO NOT KNOW WHETHER THE INCREASED RISK FOR EPILEPSY AND COGNITIVE DEFICITS SHARE COMMON MOLECULAR AND CELLULAR BASIS. THIS IS A MAJOR GAP IN OUR UNDERSTANDING AND IMPEDES THE DEVELOPMENT OF EFFECTIVE TREATMENTS OF DS-RELATED DISEASES. MANY OF THE DS-RELATED NEUROLOGICAL CONDITIONS ARE RELATED TO DYSREGULATED GABAERGIC SYSTEMS. PREVIOUS STUDIES BY OTHERS AND OURS HAVE SHOWN THAT EXCESSIVE FUNCTIONS OF GABAERGIC SYNAPSES IMPAIR SYNAPTIC PLASTICITY IN THE HIPPOCAMPUS AND THE COGNITIVE PERFORMANCES IN DS MOUSE MODELS. ON THE OTHER HAND, DYSREGULATED GABAERGIC SYSTEMS ARE ALSO A MAJOR CONTRIBUTOR TO EPILEPSY. THESE RESULTS INDICATED THAT GABAERGIC DYSFUNCTION AND ALTERED CONNECTIVITY MIGHT BE KEY TO THE COMORBIDITY OF COGNITIVE DEFICITS AND EPILEPSY IN DS. RECENTLY, WE FOUND THAT THE TRIPLICATION OF DOWN SYNDROME CELL ADHESION MOLECULE (DSCAM) IS A MAJOR CAUSE OF THE INCREASED GABAERGIC SYNAPSES AND ENHANCED GABAERGIC SYNAPTIC TRANSMISSION IN THE NEOCORTEX OF DS MOUSE MODELS. DSCAM VARIANTS ARE STRONGLY ASSOCIATED WITH COGNITIVE ABILITIES, RAISING THE POSSIBILITY THAT DSCAM CONTRIBUTES TO THE COMORBIDITY OF DS DISEASES THAT ARE CAUSED BY DYSREGULATED GABAERGIC SYSTEMS. THE OBJECTIVE OF THE PROPOSED STUDY IS TO IDENTIFY MOLECULAR REGULATORS OF GABAERGIC SYSTEMS THAT UNDERLIE COMORBIDITIES IN DS. THE CENTRAL HYPOTHESIS IS THAT DSCAM TRIPLICATION ENHANCES GABAERGIC SYNAPTIC TRANSMISSION BY INCREASING GABAERGIC SYNAPTOGENESIS AND CONTRIBUTES TO THE COMORBIDITY OF COGNITIVE DEFICITS AND EPILEPSY IN DS. THE COLLABORATIVE TEAM HAS COMPLEMENTARY STRENGTHS AND IS IN A UNIQUE POSITION FOR THE PROPOSED STUDY. THE PROPOSED RESEARCH IS INNOVATIVE BECAUSE IT WILL (1) IDENTIFY A NOVEL MOLECULAR MECHANISM THAT UNDERLIES THE COMORBIDITY OF COGNITIVE DEFICITS AND EPILEPSY IN DS; (2) PROVIDE THE FIRST COMPLETE CHARACTERIZATION OF THE ACTIVITY DYNAMICS OF CELL-TYPE SPECIFIC POPULATIONS OF THE DS HIPPOCAMPUS IN VIVO; (3) APPLY CUTTING-EDGE SPATIAL TRANSCRIPTOMIC TECHNIQUES TO PROVIDE A UNIQUE TRANSCRIPTOMIC PROFILE WITH SPATIAL RESOLUTION IN A DS MOUSE MODEL. THIS RESEARCH IS SIGNIFICANT BECAUSE ITS SUCCESSFUL COMPLETION WILL IDENTIFY THE MOLECULAR REGULATORS OF THE GABAERGIC SYSTEM IN THE DS HIPPOCAMPUS AND DISCOVER THEM AS COMMON CONTRIBUTORS TO THE COMORBIDITIES BETWEEN EPILEPSY AND INTELLECTUAL DISABILITY IN DS. THIS KNOWLEDGE WILL OFFER INSIGHTS INTO THE DEVELOPMENT OF THERAPEUTIC TREATMENTS THAT TARGET THESE DS-RELATED CONDITIONS. THE KNOWLEDGE WILL ALSO PROVIDE INSIGHTS INTO OTHER NEUROLOGICAL DISORDERS.

Posted 6/25/24, 12:00 AM